Ignite Creation Date:
2025-12-24 @ 11:25 PM
Ignite Modification Date:
2025-12-25 @ 9:11 PM
Study NCT ID:
NCT01609556
Status:
COMPLETED
Last Update Posted:
2021-02-17
First Post:
2012-05-30
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors
Sponsor:
ImmunoGen, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-06-28
Start Date Type:
ACTUAL
Primary Completion Date:
2018-03-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-03-19
Completion Date Type:
ACTUAL
First Submit Date:
2012-05-30
First Submit QC Date:
None
Study First Post Date:
2012-06-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-02-01
Results First Submit QC Date:
None
Results First Post Date:
2021-02-17
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-01-27
Last Update Post Date:
2021-02-17
Last Update Post Date Type:
ACTUAL